| 11.07 07:00 | dpa-AFX: GNW-Adhoc: Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential |
| 02.07 07:00 | dpa-AFX: GNW-Adhoc: Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial |
| 07.06 07:00 | dpa-AFX: GNW-Adhoc: Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell engagers from Marengo's Tri-STAR platform |
| 06.06 14:30 | dpa-AFX: GNW-Adhoc: Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer |
| 05.06 08:00 | dpa-AFX: GNW-Adhoc: Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis |
| 02.05 07:30 | dpa-AFX: GNW-Adhoc: Ipsen appoints Keira Driansky as EVP, President of North America |
| 24.04 07:00 | dpa-AFX: GNW-Adhoc: Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance |
| 22.04 07:00 | dpa-AFX: GNW-Adhoc: Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases |
| 02.04 07:00 | dpa-AFX: GNW-Adhoc: Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors |
| 08.02 06:58 | dpa-AFX: GNW-Adhoc: Building on solid FY 2023 results, Ipsen anticipates four launches in 2024 |
| 22.01 23:00 | dpa-AFX: GNW-Adhoc: Latest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024 |
| 07.12 07:00 | dpa-AFX: GNW-Adhoc: Capital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid-term outlook |
| 07.12 07:00 | dpa-AFX: GNW-Adhoc: Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC |
| 20.11 05:46 | dpa-AFX: *JEFFERIES SENKT IPSEN AUF 'HOLD' (BUY) - ZIEL 116 (130) EUR |
| 20.11 05:46 | dpa-AFX: *JEFFERIES CUTS IPSEN TO 'HOLD' (BUY) - PRICE TARGET 116 (130) EUR |
| 13.11 22:30 | dpa-AFX: GNW-Adhoc: Results from Ipsen's ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine |
| 26.10 07:00 | dpa-AFX: GNW-Adhoc: Ipsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year guidance |
| 23.10 07:00 | dpa-AFX: GNW-Adhoc: Ipsen updates on E.U. Marketing Authorisation Application for odevixibat in Alagille syndrome |
| 03.10 18:00 | dpa-AFX: GNW-Adhoc: Ipsen updates on QM-1114 regulatory process |
| 04.09 07:00 | dpa-AFX: GNW-Adhoc: Ipsen nominates Pascal Touchon to its Board of Directors as new independent director |
|
|
